Inflammation, Brain Clinical Trial
Verified date | April 2018 |
Source | Beth Israel Deaconess Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The protocol is to draw peripheral blood from healthy volunteers for in vitro studies. The aims of these in vitro studies are to determine the cellular and intracellular mechanisms by which hypertonic saline and ATP release regulate neutrophil and lymphocyte functions.
Status | Completed |
Enrollment | 100 |
Est. completion date | December 15, 2017 |
Est. primary completion date | December 15, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - any healthy volunteer Exclusion Criteria: - pregnancy - needing/using drugs - inflammatory or infectious complications |
Country | Name | City | State |
---|---|---|---|
United States | BIDMC | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Beth Israel Deaconess Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Immune cells will be studied in vitro to learn about basic mechanisms of immune cell signaling. | The purpose of this study is to obtain blood from healthy subjects (volunteers) for in vitro studies to explore how immune cells function. Cells will be isolated and subjected to various tests including stimuli that simulate immune cell activation in health and disease. Subjects will not be subjected to any treatments. Only some of the cells (leukocytes) in the blood will be studied. For example, activation events such as cytokine production, the ability of leukocytes (=immune cells) to detect and respond to bacterial products will be assessed. No identifiable information about study subjects will be kept. | Blood is collected as needed; time frame: indefinitely. Blood used between 1-7 days after blood draws. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03242395 -
PRIME: Cognitive Outcome Following Major Burns
|
N/A | |
Recruiting |
NCT04032626 -
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
|
Phase 2 | |
Completed |
NCT04002219 -
Efficacy Evaluation of the Mushroom Beverage on Emotion Regulation
|
N/A | |
Not yet recruiting |
NCT06177028 -
MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
|
Phase 2 | |
Active, not recruiting |
NCT05515640 -
Dysautonomia and Systemic Interactions in Traumatic Brain Injury
|